Evidence map›Paper›PMID 39383194›Full record

ReviewThe British journal of radiology2026

Evolving SPECT-CT technology.

Kathy P Willowson, Dale L Bailey

Abstract readReview
In one paragraph

Review in The British journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Nuclear medicine in the operating room: present and future.The British journal of radiology · 2026
    Review
  3. Article
  4. Review
  5. Quantification in bone SPECT/CT.Frontiers in nuclear medicine · 2026
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kathy P WillowsonDepartment of Nuclear Medicine, Royal North Shore Hospital, Sydney, NSW 2065, Australia.ORCID 0000-0002-2195-0596
Dale L BaileyDepartment of Nuclear Medicine, Royal North Shore Hospital, Sydney, NSW 2065, Australia.ORCID 0000-0001-9154-7957

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Both hardware and software developments have seen single photon emission CT (SPECT)/X-ray CT technology grow at a rapid rate. Such growth has been fuelled by the need for clinical applications and has provided inspiration for clinical developments, particularly with the expanding role of theranostics. Developments such as whole-body quantitative reconstructions, digital detectors, and recent multidetector 3D geometry have allowed SPECT to become comparable to PET on a number of fronts, with a particularly powerful role in biodistribution and dosimetry studies for both planning and evaluating radionuclide therapy. Whilst there remain fundamental challenges for SPECT such the limited spatial resolution and sensitivity, the unique opportunity to image long-lived radioisotopes and simultaneous multi-tracer studies, together with easily accessible equipment, makes SPECT/CT a valuable clinical asset. This review discusses developments in SPECT/CT technology and their clinical impact.

Indexed as

Single Photon Emission Computed Tomography Computed TomographyTomography, Emission-Computed, Single-PhotonHumansCTimaging technologySPECT

Identifiers

PMID39383194
PMCPMC13274653

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.